Wellgistics Health, Inc. Announces Pricing of $4.0 Million Initial Public Offering
Wellgistics Health has announced the pricing of its Initial Public Offering (IPO) of 888,889 ordinary shares at $4.50 per share, aiming to raise gross proceeds of $4.0 million. The company's shares have been approved for listing on the Nasdaq Capital Market under the ticker symbol WGRX, with trading expected to commence on February 21, 2025.
The offering, conducted on a firm commitment basis, is expected to close around February 24, 2025. Craft Capital Management and D. Boral Capital are serving as underwriters. The company plans to use the net proceeds for general corporate purposes, including working capital, marketing initiatives, and capital expenditures. The IPO aims to increase capitalization, financial flexibility, marketplace visibility, and create a public market for Common Stock.
Wellgistics Health ha annunciato il prezzo della sua Offerta Pubblica Iniziale (IPO) di 888.889 azioni ordinarie a $4,50 per azione, con l'obiettivo di raccogliere proventi lordi di $4,0 milioni. Le azioni della società sono state approvate per la quotazione sul Nasdaq Capital Market con il simbolo ticker WGRX, e si prevede che le negoziazioni inizino il 21 febbraio 2025.
L'offerta, condotta su base di impegno fermo, dovrebbe chiudere intorno al 24 febbraio 2025. Craft Capital Management e D. Boral Capital stanno fungendo da sottoscrittori. La società prevede di utilizzare i proventi netti per scopi aziendali generali, inclusi capitale circolante, iniziative di marketing e spese in conto capitale. L'IPO mira ad aumentare la capitalizzazione, la flessibilità finanziaria, la visibilità nel mercato e a creare un mercato pubblico per le azioni ordinarie.
Wellgistics Health ha anunciado el precio de su Oferta Pública Inicial (IPO) de 888,889 acciones ordinarias a $4.50 por acción, con el objetivo de recaudar ingresos brutos de $4.0 millones. Las acciones de la compañía han sido aprobadas para su cotización en el Nasdaq Capital Market bajo el símbolo de cotización WGRX, y se espera que la negociación comience el 21 de febrero de 2025.
La oferta, realizada en una base de compromiso firme, se espera que cierre alrededor del 24 de febrero de 2025. Craft Capital Management y D. Boral Capital están actuando como suscriptores. La compañía planea utilizar los ingresos netos para fines corporativos generales, incluyendo capital de trabajo, iniciativas de marketing y gastos de capital. La IPO tiene como objetivo aumentar la capitalización, la flexibilidad financiera, la visibilidad en el mercado y crear un mercado público para las acciones ordinarias.
Wellgistics Health는 보통주 888,889주를 주당 $4.50에 공모하는 상장공모(IPO) 가격을 발표했으며, 총 $4.0 백만을 모금할 계획입니다. 회사의 주식은 Nasdaq Capital Market에 WGRX라는 티커 기호로 상장 승인을 받았으며, 거래는 2025년 2월 21일에 시작될 예정입니다.
이번 공모는 확정 약정 방식으로 진행되며, 2025년 2월 24일 경에 마감될 것으로 예상됩니다. Craft Capital Management와 D. Boral Capital가 인수인으로 활동하고 있습니다. 회사는 순수익을 일반 기업 용도로 사용하고, 운영 자본, 마케팅 이니셔티브 및 자본 지출을 포함할 계획입니다. IPO는 자본금 증가, 재무 유연성, 시장 가시성 증대 및 보통주에 대한 공개 시장을 창출하는 것을 목표로 합니다.
Wellgistics Health a annoncé le prix de son Offre Publique Initiale (IPO) de 888 889 actions ordinaires à 4,50 $ par action, visant à lever des produits bruts de 4,0 millions $. Les actions de la société ont été approuvées pour une cotation sur le Nasdaq Capital Market sous le symbole boursier WGRX, avec un début de négociation prévu pour le 21 février 2025.
L'offre, réalisée sur une base d'engagement ferme, devrait se clôturer aux alentours du 24 février 2025. Craft Capital Management et D. Boral Capital agissent en tant que souscripteurs. La société prévoit d'utiliser les produits nets à des fins corporatives générales, y compris le fonds de roulement, les initiatives marketing et les dépenses d'investissement. L'IPO vise à augmenter la capitalisation, la flexibilité financière, la visibilité sur le marché et à créer un marché public pour les actions ordinaires.
Wellgistics Health hat den Preis für ihr Initial Public Offering (IPO) von 888.889 Stammaktien zu je 4,50 $ bekannt gegeben, mit dem Ziel, einen Bruttoerlös von 4,0 Millionen $ zu erzielen. Die Aktien des Unternehmens wurden für die Notierung am Nasdaq Capital Market unter dem Tickersymbol WGRX genehmigt, und der Handel soll am 21. Februar 2025 beginnen.
Das Angebot, das auf fester Verpflichtungsbasis durchgeführt wird, wird voraussichtlich um den 24. Februar 2025 abgeschlossen. Craft Capital Management und D. Boral Capital fungieren als Underwriter. Das Unternehmen plant, die Nettomittel für allgemeine Unternehmenszwecke zu verwenden, einschließlich Betriebskapital, Marketinginitiativen und Investitionsausgaben. Die IPO zielt darauf ab, die Kapitalisierung, finanzielle Flexibilität, Sichtbarkeit im Markt zu erhöhen und einen öffentlichen Markt für Stammaktien zu schaffen.
- Successful IPO pricing at $4.50 per share
- Nasdaq Capital Market listing approval secured
- $4.0 million expected gross proceeds from IPO
- Firm commitment basis offering structure
- Small offering size of only $4.0 million
- Potential dilution for future shareholders
Insights
This micro-cap IPO presents an intriguing yet cautionary case in the healthcare technology sector. The
The structure and timing of this offering reveal several critical insights: First, the firm commitment underwriting, while positive, typically comes with higher costs for smaller offerings, potentially consuming a significant portion of the raised capital in fees and expenses. Second, the stated use of proceeds for "general corporate purposes" lacks specificity, which is unusual for a public offering and may indicate immediate growth opportunities or a need for working capital rather than strategic expansion.
The healthcare technology sector has seen mixed reception for micro-cap IPOs, with successful companies typically requiring substantial capital for growth and R&D.
The timing of this IPO amid current market conditions and the healthcare technology sector's evolution presents both opportunities and challenges. While public market access can provide future financing flexibility through follow-on offerings, micro-cap companies often struggle with trading liquidity and analyst coverage, which can impact their ability to raise additional capital efficiently.
Tampa, Florida, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the pricing of its initial public offering (the "Offering") of 888,889 ordinary shares at a public offering price of
The Company expects to receive aggregate gross proceeds of
The Offering is being conducted on a firm commitment basis. Craft Capital Management LLC and D. Boral Capital LLC acted as underwriters for the Offering (the “Underwriters”). Dykema Gossett PLLC is acting as securities counsel to the Company, and Sichenzia Ross Ferrance Carmel LLP is acting as securities counsel to the Underwriters in connection with the Offering.
A registration statement on Form S-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-280925) and was declared effective by the SEC on February 14, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the prospectus relating to the Offering may be obtained, when available, from Craft Capital Management LLC by standard mail to Craft Capital Management LLC, 377 Oak St, Lower Concourse, Garden City, NY 11530 or by email at info@craftcm.com, or by telephone at +1(516)-833-1325; or from D. Boral Capital LLC by standard mail to D. Boral Capital LLC, 590 Madison Ave 39th Floor, New York, NY 10022, or by email at info@dboralcapital.com, or by telephone at +1(212)-970-5150. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov.
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Wellgistics Health, Inc.
Wellgistics Health is a holding company for existing and future planned operating companies centered around healthcare technology and pharmaceutical services. It seeks to be a micro health ecosystem, with a portfolio of companies consisting of a technology platform, pharmacy, and wholesale operations that provide novel prescription hub and clinical services. Wellgistics Health is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, Wellgistics Health intends to shift the dynamic of pharmaceutical care to revolve around the patient for a wide range of therapeutic conditions by offering a full spectrum of integrated solutions as a result of leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from “specialty-lite” to general maintenance conditions. For more information, please visit the Company’s website: https://wellgisticshealth.com/
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the expected trading of its Ordinary Shares on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
FAQ
What is the IPO price for Wellgistics Health (WGRX) shares?
How many shares is Wellgistics Health (WGRX) offering in its IPO?
When will WGRX stock begin trading on Nasdaq?
How much money is Wellgistics Health (WGRX) raising in its IPO?
What will Wellgistics Health use the WGRX IPO proceeds for?
When is the expected closing date for the WGRX IPO?
